IceCure Medical shareholders approve meeting agenda

IceCure Medical Ltd. held its Annual and Special General Meeting of Shareholders on November 2, 2026.

Available on EDGAR 11/02/2026 - 04:05 PM EST Accepted by SEC EDGAR 11/02/2026 - 04:05 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

IceCure Medical Ltd. held its Annual and Special General Meeting of Shareholders on November 2, 2026. The meeting was initially adjourned because a quorum was not present at 5:00 p.m. Israel time. The adjourned meeting was held at 6:30 p.m., when a quorum was present, and shareholders voted upon and approved the agenda items described in the company’s proxy statement.

Key Terms

quorum, adjourned Meeting, incorporated by reference

3 terms

quorum regulatory

"a quorum was present"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

adjourned Meeting regulatory

"At the adjourned Meeting, a quorum was present"

incorporated by reference regulatory

"is incorporated by reference into the Company’s Registration Statements"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ICCM shareholders approve at the November 2026 meeting?

ICCM shareholders approved the agenda items described in IceCure Medical Ltd.’s proxy statement at the adjourned meeting on November 2, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number: 001-40753

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F       ☐ Form 40-F

CONTENTS

On November 2, 2026, IceCure Medical Ltd. (the “Company”) convened its Annual and Special General Meeting of Shareholders (the “Meeting”).

The Meeting was initially adjourned due to there not being a required quorum present to open and conduct it at the initial time of 5:00 p.m. (Israel time). However, the adjourned Meeting was held at 6:30 p.m. (Israel time). At the adjourned Meeting, a quorum was present, and the shareholders of the Company voted upon and approved the agenda items that were described in the Company’s proxy statement for the Meeting, which were included in Exhibit 99.2 to the Company’s Report of Foreign Private Issuer on Form 6-K that the Company furnished to the Securities and Exchange Commission (“SEC”) on October 5, 2026 (the “Proxy Statement”).

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-297030, 333-290046 and 333-258660) and Form S-8 (File Nos. 333-298361, 333-270982, 333-264578, 333-262620 and 333-281587), filed with the SEC, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IceCure Medical Ltd.
Date: November 2, 2026	By:	/s/ Eyal Shamir
		Name:	Eyal Shamir
		Title:	Chief Executive Officer

2